High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according to letters seen by Reuters.
The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met the primary goal in a late-stage clinical trial.
AbbVie Inc. (NYSE:ABBV) will trade ex-dividend on July 15, putting it among the 10 Best July Dividend Stocks to Buy. On June 27, AbbVie Inc. (NYSE:ABBV) said the Food and Drug Administration approved Skyrizi for pediatric patients with psoriasis. The company said Skyrizi, or risankizumab-rzaa, can now be used in patients aged six years and […]
AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.
If you are trying to figure out whether AbbVie stock still offers value after its recent performance, starting with a clear view of price versus fundamentals is essential. AbbVie has recently traded at US$253.35, with returns of 10.1% over 7 days, 16.4% over 30 days, 10.5% year to date, 40.9% over 1 year, 109.0% over 3 years and 165.3% over 5 years, which has naturally focused attention on whether the current price fairly reflects the business. Recent headlines have focused on AbbVie’s...
AbbVie (NYSE:ABBV) received positive opinions from the European Medicines Agency's CHMP for RINVOQ in severe alopecia areata and non-segmental vitiligo. If approved, RINVOQ could become the first systemic therapy for non-segmental vitiligo in Europe. The new indications target areas with high unmet medical need in dermatology and immunology. AbbVie has been active across immunology, gastroenterology and virology, and RINVOQ is already a core asset in its portfolio. These fresh CHMP...
In the past five years, this top healthcare stock has risen by close to 130%.
AbbVie wins positive CHMP opinions for Rinvoq in severe alopecia areata and non-segmental vitiligo, with EU decisions expected in the coming months.
SYRE has surged on pipeline progress and a strong cash position, but with no product revenue and key trial data still ahead, is the risk already priced in?
SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but its future still hinges on clinical trial results.
The investment case for Spyre Therapeutics is built around a straightforward but high-risk question: can its broad IBD pipeline produce meaningful clinical proof-of-concept data?
LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.
AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]
AbbVie Inc. (NYSE:ABBV) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 23, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced that Health Canada approved Boey for the temporary improvement of moderate to severe lines between the eyebrows in adults. Boey is the first and only approved botulinum […]
AbbVie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. AbbVie Inc. (NYSE:ABBV) and Apogee Therapeutics announced on June 22 their entry into a definitive agreement under which AbbVie Inc. (NYSE:ABBV) will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across immunological and inflammatory diseases, which includes […]
It has been a banner year for biotech buyouts, and these are two of the prime targets.
What does retirement look like for someone who genuinely has no desire to leave home? No snowbird condo in Florida. No Viking river cruises. No RV parked outside Yellowstone. Just Chicago. The Cubs in the summer, the museums when the weather turns, dinner at the neighborhood Italian restaurant, church on Sunday, and grandchildren across town ... The Homebody Portfolio: How Much Does Retirement Cost When You Never Leave Chicago?
Earlier this week, AbbVie reported European Commission approvals extending Skyrizi to children with moderate to severe plaque psoriasis and making Maviret the only therapy cleared in the EU for both acute and chronic hepatitis C infection from age three. These label expansions broaden AbbVie’s reach in immunology and virology by opening earlier treatment windows and adding pediatric populations in high-need diseases. We’ll now explore how Skyrizi’s new pediatric indication and Maviret’s...
AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?
Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have quietly positioned themselves as prime acquisition targets, but only one offers the rare combination of a depressed valuation and a commercial product already gaining ground.
AbbVie Inc. (NYSE:ABBV) is included among the Top 10 Blue Chip Stocks with Growing Dividends. On June 23, Canaccord raised its price recommendation on AbbVie Inc. (NYSE:ABBV) to $273 from $265. It reiterated a Buy rating on the shares. The firm updated its model following AbbVie’s announced acquisition of Apogee Therapeutics (APGE). Canaccord said the […]
I hit the buy button on AbbVie (NYSE:ABBV) again last week, and I will hit it again the next time June’s macro noise hands me a discount. While short-term traders chase headlines around sticky 4.2% inflation and a softening jobs picture, I keep adding shares of a cash machine that does not care which way ... Why I Can’t Stop Buying This Unstoppable Dividend Juggernaut
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
